深圳市龙岗区3月龄至6岁儿童DTaP疫苗预防百日咳效果:病例对照研究
该研究采用检测阴性设计的1:2匹配病例对照研究,纳入2013-2023年深圳市龙岗区3月龄至6岁实验室确诊百日咳病例219例和阴性对照438例,估算DTaP疫苗的真实世界保护效果。结果显示总体VE为72.60%(95%CI:60.12%,81.18%),且VE随剂次增加而升高,完成四剂后至少36-47个月仍保持76.10%的保护。
要点
- 3月龄至6岁儿童DTaP总体VE为72.60%(95%CI:60.12%,81.18%)
- 四剂次VE最高达79.77%,提示应确保四剂全程接种
- 完成四剂后36-47个月保护仍达76.10%,免疫衰减证据有限
核心结论
- DTaP疫苗保护效果随剂次增加而升高,完成四剂全程接种对3月龄至6岁儿童提供稳健保护。
- 完成基础免疫后随时间推移VE可能下降,但证据受估计精度限制,不能得出明确免疫衰减结论。
研究设计与样本
- 研究采用检测阴性设计的1:2匹配病例对照研究。
- 病例为2013-2023年深圳市龙岗区医疗机构报告的3月龄至6岁实验室确诊百日咳患者,对照为同机构检测阴性、同性别同月龄儿童。
- 先验样本量计算为140例病例和280例对照,假设VE为85%、90%把握度、双侧α=0.05;实际纳入219例病例和438例对照。
- 采用条件logistic回归估计DTaP疫苗效果。
主要发现
- DTaP预防3月龄至6岁儿童百日咳的总体VE为72.60%(95%CI:60.12%,81.18%)。
- 1-2剂次VE为65.76%(95%CI:45.89%,78.54%),3剂次VE为59.16%(95%CI:29.45%,76.72%),4剂次VE为79.77%(95%CI:68.75%,87.05%)。
- 四剂次接种队列分析提示VE随时间可能下降,但各时间层置信区间大幅重叠,应谨慎解读。
- 完成接种后36-47个月保护效果仍为76.10%。
临床怎么用
- 应确保儿童按程序完成四剂DTaP全程接种,以在生命早期获得稳健保护。
- 对3月龄至6岁儿童应关注剂次完成情况,四剂次显示最高保护效果。
- 监测数据显示病例年龄分布从3-11月龄婴儿为主转向3-6岁儿童为主,提示需关注该年龄组免疫状态。
局限性
- 四剂次接种后VE随时间下降的趋势受估计精度限制,各时间层置信区间大幅重叠,免疫衰减证据不充分。
- VE随时间变化呈非线性趋势,不能得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pertussis is a highly contagious respiratory disease caused by Bordetella pertussis. In recent years, it has resurged in many parts of the world. Surveillance data from Longgang District, Shenzhen (2017-2023) show that the age distribution of cases has shifted from being dominated by infants aged 3-11 months (100 % in 2017) to children aged three to six years (>50 % in 2023), suggesting that waning vaccine-induced immunity may be a key driver of the resurgence. This study aimed to estimate the real-world effectiveness of DTaP among children aged three months to six years to inform evidence-based optimisation of immunization strategies. METHODS: We employed a test-negative design within a 1:2 matched case-control framework. Cases were defined as all laboratory-confirmed pertussis patients aged three months to six years reported by healthcare facilities in Longgang District, Shenzhen, between 2013 and 2023. Controls were children who tested negative for pertussis and attended the same healthcare facility as their matched case, were of the same sex and exact age (in months), and were selected using a random-number-based matching procedure. The required sample size (140 cases and 280 controls) was calculated a priori, assuming an expected vaccine effectiveness of 85 %, 90 % power, and a two-sided α of 0.05. Data collection continued until the target sample size was reached. Conditional logistic regression was used to estimate the effectiveness of the DTaP vaccine. RESULTS: A total of 219 cases and 438 controls were included. The overall VE of DTaP in preventing pertussis in children aged three months to six years was 72.60 % (95 % CI:60.12 %,81.18 %). The VE for one to two doses, three doses, and four doses of DTaP was 65.76 % (95 % CI:45.89 %,78.54 %), 59.16 % (95 %CI,29.45 %,76.72 %), and 79.77 % (95 %CI,68.75 %,87.05 %), respectively. Analysis of the four-dose vaccinated cohort suggested a potential decline in VE over time; however, this trend should be interpreted with caution as confidence intervals overlapped substantially across time strata. Nevertheless, the protective effect remained at 76.10 % even 36-47 months after completing vaccination. CONCLUSIONS: VE increased with the number of doses administered. Although a gradual decline in VE over time was suggested after completing the primary series, conclusive evidence for waning immunity was limited by the precision of our estimates, which indicated a nonlinear trend. Our findings underscore the importance of ensuring universal completion of the four-dose DTaP series, which provided robust protection for at least the first four years of life.
引用
- Wang XL, Xu JQ, Ye BL, et al. Estimating diphtheria, acellular pertussis, tetanus vaccine (DTaP) effectiveness in preventing pertussis in children aged three months to six years old in Shenzhen area, China, case control study. Vaccine. 2025. PMID: 41343986. doi:10.1016/j.vaccine.2025.128024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。